Siim Land Podcast #492 I Read All the Human Studies on the Most Popular Peptides - Here's What the Data Shows
Feb 14, 2026
A fast-paced tour of the human clinical evidence behind popular peptides. Topics include regenerative and brain-targeting peptides, growth-hormone mimetics, and aesthetic compounds. He compares Russian and Western trial data, highlights which peptides have real human trials versus only animal data, and warns about sourcing and safety concerns.
AI Snips
Chapters
Transcript
Episode notes
Cerebrolysin Speeds Short‑Term Brain Recovery
- Cerebrolysin has decades of clinical use and RCTs showing short‑term cognitive and functional improvements after stroke or brain injury.
- Benefits appear time‑limited and don't reduce mortality, but short‑term recovery support is consistent.
CMAX: Russian Cognitive Peptide With Limited Replication
- CMAX is used in Russia for neuropathy and cognitive disorders with small trials suggesting benefit, but lacks Western replication.
- Mechanisms include upregulating BDNF and monoamines, and intranasal delivery is available.
CJC‑1295 Strongly Raises GH, Safety Context Matters
- CJC‑1295 (Ipamorelin) reliably raises GH and IGF‑1 in humans manyfold and sustains levels for days.
- Trials were halted after a sudden death in phase 2, so safety context matters despite clear hormonal effects.